These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 22497737)

  • 1. Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium.
    Pils D; Hager G; Tong D; Aust S; Heinze G; Kohl M; Schuster E; Wolf A; Sehouli J; Braicu I; Vergote I; Cadron I; Mahner S; Hofstetter G; Speiser P; Zeillinger R
    Cancer Sci; 2012 Jul; 103(7):1334-41. PubMed ID: 22497737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.
    Pils D; Bachmayr-Heyda A; Auer K; Svoboda M; Auner V; Hager G; Obermayr E; Reiner A; Reinthaller A; Speiser P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Berger A; Cacsire Castillo-Tong D; Zeillinger R
    Eur J Cancer; 2014 Jan; 50(1):99-110. PubMed ID: 24176298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
    Chekerov R; Braicu I; Castillo-Tong DC; Richter R; Cadron I; Mahner S; Woelber L; Marth C; Van Gorp T; Speiser P; Zeillinger R; Vergote I; Sehouli J
    Int J Gynecol Cancer; 2013 Feb; 23(2):268-75. PubMed ID: 23358178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.
    Aust S; Auer K; Bachmayr-Heyda A; Denkert C; Sehouli J; Braicu I; Mahner S; Lambrechts S; Vergote I; Grimm C; Horvat R; Castillo-Tong DC; Zeillinger R; Pils D
    Mol Cancer; 2014 Mar; 13():67. PubMed ID: 24655477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?
    Ataseven B; Harter P; Grimm C; Heitz F; Heikaus S; Traut A; Kahl A; Kurzeder C; Prader S; du Bois A
    Gynecol Oncol; 2016 Aug; 142(2):243-7. PubMed ID: 27208538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type.
    Toptas T; Pestereli E; Erol O; Bozkurt S; Erdogan G; Simsek T
    Int J Gynecol Cancer; 2016 Jul; 26(6):1012-9. PubMed ID: 27206284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiles as prognostic markers in women with ovarian cancer.
    Jochumsen KM; Tan Q; Høgdall EV; Høgdall C; Kjaer SK; Blaakaer J; Kruse TA; Mogensen O
    Int J Gynecol Cancer; 2009 Oct; 19(7):1205-13. PubMed ID: 19823056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
    APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
    Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
    Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved classification of epithelial ovarian cancer: results of 3 danish cohorts.
    Steffensen KD; Waldstrøm M; Grove A; Lund B; Pallisgård N; Jakobsen A
    Int J Gynecol Cancer; 2011 Dec; 21(9):1592-600. PubMed ID: 21926912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.
    Peng DX; Luo M; Qiu LW; He YL; Wang XF
    Oncol Rep; 2012 Apr; 27(4):1238-44. PubMed ID: 22246341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.
    Ma M; Yu N
    Tohoku J Exp Med; 2017 Mar; 241(3):239-247. PubMed ID: 28344213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery.
    Hosono S; Kajiyama H; Mizuno K; Sakakibara K; Matsuzawa K; Takeda A; Kawai M; Nagasaka T; Kikkawa F
    Int J Clin Oncol; 2011 Oct; 16(5):524-32. PubMed ID: 21431342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pathological characteristics and prognosis of 664 patients with epithelial ovarian cancer: a retrospective analysis].
    Hou MM; Chen Y; Wu YK; Xi MR
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Sep; 45(5):859-62, 875. PubMed ID: 25341355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer.
    Le Page C; Ouellet V; Quinn MC; Tonin PN; Provencher DM; Mes-Masson AM
    Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):913-20. PubMed ID: 18398031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Gab1 Is Associated with Poor Prognosis of Patients with Epithelial Ovarian Cancer.
    Hu L; Liu R
    Tohoku J Exp Med; 2016 Jul; 239(3):177-84. PubMed ID: 27302321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.